Compare GTS Internasional Tbk. (GTSI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GTS Internasional Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? GTS Internasional Tbk. trades at Rp165 (market cap 2.64T, 20.64M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: GTS Internasional Tbk. is far larger — about 25.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| GTSI | SCPI | |
|---|---|---|
Market Cap | 2.64T | 104.4B |
Volume | 20.64M | — |
Lot | 206.42K | — |
Turnover | 3.34B | — |
Average Price | 161.78 | — |
Value | 3.34B | — |
Indicative Equilibrium Price | 165 | — |
Indicative Equilibrium Volume | 4.9K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GTS Internasional Tbk.
PT GTS Internasional Tbk (the “Company”) was established based on Notarial Deed No. 32 dated June 29, 2012 of Martina, S.H. The Company started its commercial operations in August 2019. The Company’s parent entity is PT Hateka Trans Internasional and ultimate parent entity is PT Humpuss Intermoda Transportasi Tbk.
Read more on GTSI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
